Mouse models of myeloproliferative neoplasms: JAK of all grades (Q28744478)

From Wikidata

Jump to navigation Jump to search

scientific article (publication date: May 2011)

edit

Language	Label	Description	Also known as
English	Mouse models of myeloproliferative neoplasms: JAK of all grades	scientific article (publication date: May 2011)

Statements

instance of

scholarly article

0 references

review article

6 references

stated in

PubMed

retrieved

3 April 2019

stated in

PubMed

retrieved

20 June 2019

stated in

PubMed

retrieved

19 September 2019

stated in

PubMed

retrieved

28 September 2019

stated in

PubMed

retrieved

22 July 2020

stated in

PubMed

retrieved

3 December 2020

title

Mouse models of myeloproliferative neoplasms: JAK of all grades (English)

0 references

main subject

myeloproliferative disorders

5 references

stated in

PubMed

retrieved

3 April 2019

stated in

PubMed

retrieved

20 June 2019

stated in

PubMed

retrieved

19 September 2019

stated in

PubMed

retrieved

28 September 2019

stated in

PubMed

retrieved

22 July 2020

biomedical investigative technique

1 reference

stated in

PubMed

retrieved

19 September 2019

enzyme

1 reference

stated in

PubMed

retrieved

28 September 2019

bone marrow neoplasm

1 reference

stated in

PubMed

retrieved

22 July 2020

tumor of hematopoietic and lymphoid tissues

1 reference

stated in

PubMed

retrieved

22 July 2020

animal disease model

1 reference

stated in

PubMed

retrieved

3 December 2020

author

David Kent

series ordinal

2

object named as

David G Kent

0 references

author name string

Juan Li

series ordinal

1

0 references

Edwin Chen

series ordinal

3

0 references

Anthony R Green

series ordinal

4

0 references

language of work or name

English

0 references

publication date

May 2011

0 references

1 May 2011

6 references

stated in

PubMed Central

retrieved

3 April 2019

stated in

PubMed Central

retrieved

20 June 2019

stated in

PubMed Central

retrieved

19 September 2019

stated in

PubMed Central

retrieved

28 September 2019

stated in

PubMed Central

retrieved

22 July 2020

stated in

PubMed Central

retrieved

3 December 2020

published in

Disease Models & Mechanisms

6 references

stated in

PubMed Central

retrieved

3 April 2019

stated in

PubMed Central

retrieved

20 June 2019

stated in

PubMed Central

retrieved

19 September 2019

stated in

PubMed Central

retrieved

28 September 2019

stated in

PubMed Central

retrieved

22 July 2020

stated in

PubMed Central

retrieved

3 December 2020

volume

4

0 references

issue

3

0 references

page(s)

311-7

0 references

cites work

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097453

retrieved

16 March 2017

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097453

retrieved

16 March 2017

Chronic myeloproliferative disorders

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097453

retrieved

16 March 2017

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097453

retrieved

7 April 2017

Mutation in TET2 in myeloid cancers

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097453

retrieved

7 April 2017

A gain-of-function mutation of JAK2 in myeloproliferative disorders

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097453

retrieved

7 April 2017

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097453

retrieved

7 April 2017

Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097453

retrieved

3 June 2018

Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097453

retrieved

3 June 2018

JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097453

retrieved

3 June 2018

Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097453

retrieved

3 June 2018

Clinical relevance of JAK2 (V617F) mutant allele burden

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097453

retrieved

3 June 2018

Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097453

retrieved

3 June 2018

A role for JAK2 mutations in myeloproliferative diseases

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097453

retrieved

3 June 2018

Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097453

retrieved

3 June 2018

Characterization of murine JAK2V617F-positive myeloproliferative disease

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097453

retrieved

3 June 2018

JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097453

retrieved

3 June 2018

The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097453

retrieved

3 June 2018

Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097453

retrieved

3 June 2018

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097453

retrieved

3 June 2018

Identification of an acquired JAK2 mutation in polycythemia vera

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097453

retrieved

3 June 2018

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097453

retrieved

3 June 2018

Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097453

retrieved

3 June 2018

Some speculations on the myeloproliferative syndromes.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097453

retrieved

3 June 2018

Modeling the dosage effect of oncogenes in leukemogenesis

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097453

retrieved

3 June 2018

Clonal Origin of Human Tumors

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097453

retrieved

3 June 2018

Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097453

retrieved

27 November 2018

Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097453

retrieved

27 November 2018

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097453

retrieved

27 November 2018

Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097453

retrieved

27 November 2018

Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097453

retrieved

27 November 2018

The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097453

retrieved

27 November 2018

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097453

retrieved

27 November 2018

Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21558064

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Discordant distribution of JAK2V617F mutation in siblings with familial myeloproliferative disorders

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21558064

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

JAK2 impairs stem cell function?

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21558064

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21558064

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21558064

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1242/DMM.006817

1 reference

stated in

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1425130

OpenCitations bibliographic resource ID

1425130

1 reference

stated in

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1425130

PMC publication ID

3097453

1 reference

stated in

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1425130

PubMed publication ID

21558064

1 reference

stated in

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1425130

ResearchGate publication ID

51113167

0 references

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28744478&oldid=1409325527"